This ES variant, also known as the zinc-binding protein-endostatin (ZBP-ES), was approved by the China Food and Drug Administration (CFDA) to treat non-small cell lung cancer (NSCLC) patients in China in 2005 [6]. The gene discussed is ZP4; the disease is non-small cell lung carcinoma.